Lynwick Dialysis, Llc is a medicare approved dialysis facility center in Cedar Hill, Texas and it has 21 dialysis stations. It is located in Dallas county at 439 E Fm 1382, Cedar Hill, TX, 75104. You can reach out to the office of Lynwick Dialysis, Llc at (214) 414-2810. This dialysis clinic is managed and/or owned by Unknown At This Time. Lynwick Dialysis, Llc has the following ownership type - Profit. It was first certified by medicare in August, 2017. The medicare id for this facility is 452938 and it accepts patients under medicare ESRD program.
| Name | Lynwick Dialysis, Llc |
|---|---|
| Location | 439 E Fm 1382, Cedar Hill, Texas |
| No. of Dialysis Stations | 21 |
| Medicare ID | 452938 |
| Managed By | Unknown At This Time |
| Ownership Type | Profit |
| Late Shifts | No |
| 439 E Fm 1382, Cedar Hill, Texas, 75104 | |
| (214) 414-2810 | |
| Not Available |
News Archive
Nobilon, the human vaccine business unit of Schering-Plough Corporation has announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.
A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.
For decades, scientists and doctors have been searching for a cure for cancer. Now, researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have taken a significant step forward with a new concept that could ultimately result in more effective treatments.
Since antiretroviral therapy (ART) for HIV was introduced in 1996, AIDS-related morbidity and mortality has declined significantly.
Cutting pharmaceutical prices will severely reduce the number of new medications making it to market, according to a groundbreaking independent study from ESMT Competition Analysis. For the first time, the study on 'Pharmaceutical Innovation and Pricing Regulation' clearly models and quantifies the direct link between strict regulation and low innovation.
› Verified 8 days ago
| NPI Number | 1427418904 |
| Organization Name | Cedar Hill Dialysis |
| Doing Business As | Lynwick Dialysis Llc |
| Address | 439 E Fm 1382 Cedar Hill, Texas, 75104 |
| Phone Number | (214) 414-2810 |
News Archive
Nobilon, the human vaccine business unit of Schering-Plough Corporation has announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.
A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.
For decades, scientists and doctors have been searching for a cure for cancer. Now, researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have taken a significant step forward with a new concept that could ultimately result in more effective treatments.
Since antiretroviral therapy (ART) for HIV was introduced in 1996, AIDS-related morbidity and mortality has declined significantly.
Cutting pharmaceutical prices will severely reduce the number of new medications making it to market, according to a groundbreaking independent study from ESMT Competition Analysis. For the first time, the study on 'Pharmaceutical Innovation and Pricing Regulation' clearly models and quantifies the direct link between strict regulation and low innovation.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.